LivaNova shares rose 3.7% to $85.43 on Tuesday. The latest numbers provide context for that move: revenue grew 10.8% to $390.6 million in the three months ended June 30, and net income nearly quadrupled to $108.6 million.
The operating line was less cooperative. Operating income fell 8.7% to $49.5 million, pulling operating margin down to 12.7% from 15.4%. LivaNova sold more and generated a higher gross margin, but the extra sales did not make it through the business in the same proportion.
That is the filing's central trade-off. Gross margin improved to 70.1% from 67.8%, a 2.3 percentage-point lift. Research and development spending rose 13.7% to $53.7 million, and stock compensation increased 84.0% to $16.9 million. The company does not disclose a single explanation for the operating-income decline in the supplied filing facts, so the expense build is the visible operating change rather than a complete cause.
The much larger net-income jump sits below that line, not above it. Diluted earnings per share rose to $1.93 from $0.50, while diluted shares increased 2.9% to 56.3 million. The filing does not identify in the supplied facts what produced the difference between falling operating income and sharply higher net income.
The cash numbers add another layer. Cash fell 13.0% year over year to $516.6 million. Capital spending rose 76.7% on a comparable three-month basis, while free-cash-flow margin declined 4.3 percentage points. Inventory and accounts receivable grew more slowly than sales, at 4.4% and 5.0%, respectively, but that did not prevent the cash balance from shrinking.
The company’s recent annual record makes the operating-line tension more specific. Revenue reached $1.4B in 2025, up 10.7%, and annual operating margin improved to 14.4%. That is a business with a recent growth-and-margin record, but this latest three-month comparison interrupts the margin part of the pattern even as the gross margin improves.
LivaNova also finished 2025 with net cash of $290.4M, so the balance sheet is not defined by reported net debt. The latest period instead puts attention on how much of the growing business is being converted into operating profit and free cash flow, particularly as investment spending rises.
The unresolved pieces remain operating margin, capital spending, free-cash-flow margin, and the explanation for the gap between operating income and net income. For now, the three-month period offers a familiar medical-device combination with one extra wrinkle: more revenue, better gross margin, and less operating income to show for it.